Pancreatic Cancer Research

ResearcherNational Institute of Biomedical Innovation, Health and NutritionActive in the last 2 years

Hirofumi Akita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3115-9466; OpenAlex author ID A5021500931. Sources: OpenAlex.

Their work

Papers
68 (first author 9, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
141
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 4 papers · 2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 4 papers · 2019: 3 papers · 2020: 4 papers · 2021: 5 papers · 2022: 4 papers · 2023: 4 papers · 2024: 8 papers · 2025: 11 papers · 2026: 13 papers

Papers 50 of 68

  1. Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative… Co-author DOI 10.1002/ags3.70191↗
  2. Relationship Between Radiographic and Pathological Portal Vein-Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparati… Co-author DOI 10.1002/wjs.70395↗
  3. A soft tissue mass around the arteries after pancreatectomy: the association with local recurrence and the impact of neoadjuvant radiotherapy in pancreatic duc… Co-author DOI 10.1007/s00595-026-03341-w↗
  4. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Co-author DOI 10.1007/s10147-026-03071-6↗
  5. Prognostic significance of neoadjuvant gemcitabine and S-1 chemotherapy with or without concurrent radiation in patients with resectable and borderline resecta… Co-author DOI 10.1016/j.surg.2025.109864↗
  6. Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Co-author DOI 10.1038/s41598-026-48779-7↗
  7. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  8. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  9. Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis. Co-author DOI 10.1245/s10434-025-18659-x↗
  10. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). First author DOI 10.1371/journal.pone.0345459↗
  11. Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment respo… Co-author DOI 10.3892/ijo.2026.5849↗
  12. Enterococcus faecalis is involved in the progression of the early stages of latent chronic pancreatitis surrounding pancreatic cancer tissue Co-author DOI 10.64898/2026.07.20.739687↗
  13. Prohaptoglobin Promotes Pancreatic Cancer Progression by sustaining YAP Activity Co-author DOI 10.64898/2026.07.26.740853↗
  14. Discrepancy Between Radiographic and Pathological Response Assessment in Neoadjuvant Treatment for Pancreatic Cancer: A Comparison Between Neoadjuvant Chemothe… Co-author DOI 10.1002/ags3.70047↗
  15. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  16. Prognostic impact of post-neoadjuvant CA19-9 values in pancreatic cancer: more pronounced following neoadjuvant chemotherapy compared to neoadjuvant chemoradio… Co-author DOI 10.1016/j.pan.2025.06.016↗
  17. Response to the letter to the editor: "Refining the prognostic utility of CA19-9 in neoadjuvant therapy for pancreatic cancer: Emphasizing serial monitoring an… Co-author DOI 10.1016/j.pan.2025.09.033↗
  18. Response to letter to the editor: "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable or b… Co-author DOI 10.1016/j.surg.2024.109053↗
  19. Reply to letter to editor by yinfang Wu, MM about our manuscript, "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from ra… Co-author DOI 10.1016/j.surg.2024.109132↗
  20. Reply to letter to editor by Duo Yun, MD regarding our article, "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radi… Co-author DOI 10.1016/j.surg.2024.11.003↗
  21. Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases. Co-author DOI 10.1016/j.suronc.2025.102225↗
  22. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenoca… Co-author DOI 10.1038/s41598-025-23185-7↗
  23. The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.1111/cas.70087↗
  24. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Co-author DOI 10.1186/s12876-025-04108-2↗
  25. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  26. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic ca… Co-author DOI 10.1016/j.surg.2024.06.049↗
  27. Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological h… Co-author DOI 10.1016/j.suronc.2024.102103↗
  28. The preliminary analysis of lymphatic flow around the connective tissues surrounding SMA and SpA elucidates patients' oncological condition in borderline-resec… Co-author DOI 10.1186/s12893-024-02398-z↗
  29. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radi… Co-author DOI 10.1245/s10434-024-15021-5↗
  30. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  31. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  32. Circulating tumor-associated antigen-specific IFNγ+4-1BB+ CD8+ T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2024.1363568↗
  33. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-023-04531-w↗
  34. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s10147-023-02306-0↗
  35. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resec… First author DOI 10.1097/sla.0000000000005879↗
  36. DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1186/s12885-023-10512-2↗
  37. Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cnr2.1582↗
  38. N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-15196-5↗
  39. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  40. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  41. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvan… Co-author DOI 10.1002/ags3.12418↗
  42. Identification of fucosylated haptoglobin-producing cells in pancreatic cancer tissue and its molecular mechanism. Co-author DOI 10.1007/s10719-020-09970-8↗
  43. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. First author DOI 10.1016/j.canlet.2021.04.029↗
  44. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
  45. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗
  46. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Co-author DOI 10.1007/s00280-019-04005-y↗
  47. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07927-2↗
  48. Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. Co-author DOI 10.3390/cells9071645↗
  49. Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer. Co-author DOI 10.4251/wjgo.v12.i7.768↗
  50. Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revis… Co-author DOI 10.1002/ags3.12288↗

Closest collaborators

The 25 strongest of 141 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 41 shared papers, 2011–2026 · strength 5.96
  2. Hidetoshi Eguchi · 41 shared papers, 2011–2026 · strength 5.80
  3. Hidenori Takahashi · 34 shared papers, 2011–2026 · strength 5.07
  4. Daisaku Yamada · 27 shared papers, 2019–2026 · strength 4.90
  5. Yoshito Tomimaru · 24 shared papers, 2013–2026 · strength 4.17
  6. Yoshifumi Iwagami · 22 shared papers, 2013–2026 · strength 3.55
  7. Tadafumi Asaoka · 17 shared papers, 2019–2026 · strength 2.88
  8. Shinichiro Hasegawa · 14 shared papers, 2019–2026 · strength 2.87
  9. Kunihito Gotoh · 15 shared papers, 2015–2026 · strength 2.24
  10. Yosuke Mukai · 8 shared papers, 2023–2026 · strength 2.06
  11. Hiroshi Wada · 7 shared papers, 2023–2026 · strength 1.85
  12. Kazuki Sasaki · 10 shared papers, 2022–2026 · strength 1.84
  13. Masahiko Kubo · 7 shared papers, 2020–2026 · strength 1.82
  14. Masahiro Tanemura · 15 shared papers, 2011–2026 · strength 1.81
  15. Satoru Miyahara · 6 shared papers, 2024–2026 · strength 1.37
  16. Yutaka Takeda · 9 shared papers, 2011–2026 · strength 1.21
  17. Hidetoshi Eguchi · 4 shared papers, 2025–2026 · strength 0.96
  18. Masato Sakon · 9 shared papers, 2015–2024 · strength 0.94
  19. Masanori Tsujie · 5 shared papers, 2021–2026 · strength 0.87
  20. Ryoji Takada · 5 shared papers, 2018–2026 · strength 0.77
  21. Kazuyoshi Ohkawa · 5 shared papers, 2018–2026 · strength 0.77
  22. Hiroaki Nagano · 12 shared papers, 2011–2025 · strength 0.74
  23. Osamu Ishikawa · 9 shared papers, 2011–2023 · strength 0.74
  24. Eiji Miyoshi · 5 shared papers, 2015–2026 · strength 0.73
  25. Naoko Sekiguchi · 3 shared papers, 2025–2026 · strength 0.72

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.